Director Jude Anthany Joseph says it took him three floods to write 2018, his superhit Malayalam survival drama.
2018 narrated the story of the devastating Kerala floods that occurred in 2018 when people from all walks of life came together to survive the calamity.
The Tovino Thomas-starrer, which released in May, emerged as the highest-earning Malayalam film by crossing the £20 million mark at the box office.
Joseph, who recently announced his next project with Lyca Productions, said he was one of the many people affected by the August 2018 floods in Kerala. Deemed the state's worst in a century, the disaster claimed over 400 lives.
"It took me three floods to complete the script. In 2018, when the floods happened, my house drowned. I was away with my family at my sister's house and did not know about the massive rescue efforts launched by the navy and airforce because there was no internet connection," Joseph told PTI.
According to the filmmaker, he was in a "depressive state" when an NGO approached him to make a short film focusing on how people helped each other during the crisis.
Joseph said he realised a short film was not enough on the 2018 floods and decided to narrate the stories that he unearthed during his research through a feature, which he said was a "herculean task".
"After the floods, when I started writing the script... It was like self-inspiration. I had to move on, so I had to do something that would make me happy," he said, adding that his house also faced damage in 2019 and 2020 as well.
The filmmaker, whose credits include Ohm Shanthi Oshaana and Sara's, also recalled the outpour of love from the who's who of Malayalam cinema, including veteran directors Priyadarshan and T K Rajeev Kumar, in the first three weeks of the film's release.
"The most memorable thing was that wherever I would go, to a theatre or a mall, common people would come to me and they would hug me. They would take a snap with me... I was very moved by that gesture. Everybody was very emotional because they had experienced the floods," he added.
Indrans, Kunchacko Boban, Aparna Balamurali, Vineeth Sreenivasan, Asif Ali, Lal, Narain, Tanvi Ram, Sshivada, Kalaiyarasan, Aju Varghese, Siddique, Joy Mathew and Sudheesh also starred in 2018.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.